MedTrace Logo

Prevalence of Pancreatic Steatosis in Pancreatic Cystic Neoplasms and Pancreatic Adenocarcinoma

NCT06867172 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2025-03-10

No results posted yet for this study

Summary

Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS).

The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk.

The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.

Conditions

  • Pancreatic Steatosis
  • Pancreatic Cyst
  • Pancreatic Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

computerized tomography

Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.

DIAGNOSTIC_TEST

Endosonography (EUS)

EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.

Sponsors & Collaborators

  • Carol Davila University of Medicine and Pharmacy

    lead OTHER

Principal Investigators

  • Mihai Ciocirlan, MD PhD · Romanian Society of Digestive Endoscopy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2025-03-31
Completion
2025-06-30

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06867172 on ClinicalTrials.gov